Will Canary Capital's Injective ETF Filing Reverse INJ Prices as Ecosystem Accelerates?

Injective (INJ) has faced mounting selling pressure in recent weeks, with prices declining significantly from their earlier peaks. However, a major regulatory development could reshape the market outlook. Asset manager Canary Capital has filed an application with the U.S. Securities and Exchange Commission to launch a staked Injective ETF, potentially unlocking institutional capital and regulated market access for INJ investors. The question now becomes: can this regulatory milestone help stabilize INJ prices amid current weakness?

Canary Capital Advances Injective ETF Through SEC Regulatory Approval Process

In a significant move for the Injective ecosystem, Canary Capital has initiated the regulatory approval process by submitting its S-1 registration statement to the SEC for a proposed staked Injective ETF. If greenlit by regulators, the Canary Staked Injective ETF would debut on Cboe, offering investors direct exposure to INJ’s spot price alongside the ability to generate additional yield through staking rewards.

The product structure reflects institutional-grade standards. U.S. Bancorp Fund Services will function as the transfer agent and cash custodian, while BitGo Trust Company has been designated as the digital asset custodian. The ETF will reference the INJ-USD CCIXber Reference Rate price index for performance tracking. Share creation and redemption will occur in blocks of 10,000 shares, and Paralel Distributors LLC will handle marketing efforts.

This ETF filing joins a growing pipeline of crypto-related funds awaiting SEC approval for 2026, signaling continued institutional interest in regulated digital asset exposure.

Injective Ecosystem Momentum Builds on Real-World Asset Growth

Beyond the regulatory developments, the Injective ecosystem itself continues to expand at an accelerating pace. On-chain activity metrics paint a picture of robust ecosystem development. Weekly transaction counts have surged dramatically, climbing from the 0–1,000 range in 2023 to nearly 1 million transactions per week today—a testament to the platform’s growing utility across decentralized exchanges, staking, derivatives, minting operations, and NFT interactions.

A key driver of this growth has been Injective’s push into real-world asset (RWA) tokenization. In late 2025, Injective’s leadership demonstrated how a $10 billion mortgage portfolio from PAPL pineapple was successfully brought on-chain through the Injective network. The protocol is also exploring emerging use cases like pre-IPO stock trading, positioning itself at the forefront of RWA adoption within the crypto ecosystem.

These developments highlight that despite current price pressures, the underlying Injective network is experiencing significant operational growth and expanding its use cases into institutional-grade assets.

INJ Prices Under Technical Stress: Is Recovery Possible?

As of early March 2026, INJ is trading at $3.04, reflecting a 25.10% decline over the past 30 days. The broader market dynamics reveal a mixed technical picture. On shorter timeframes, the asset trades below its key moving averages (50-day, 100-day, and 200-day), indicating continued downward momentum. However, the Relative Strength Index (RSI) has fallen to levels suggesting oversold conditions, which historically can precede technical rebounds.

For traders seeking entry points, support around $3.00 could provide a tactical opportunity, with potential resistance targets around $3.50 if buying momentum rebuilds. A sustained recovery will require meaningful increases in trading volumes and potentially positive catalyst events—such as SEC approval of the proposed ETF filing—to overcome the current bearish sentiment.

The convergence of ecosystem growth metrics, institutional ETF interest, and oversold technical conditions creates a scenario where INJ prices could stabilize, though near-term volatility remains likely as the market digests these competing forces.